Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study
| Autor: | A H, Calvert, M J, Lind, S, Ghazal-Aswad, L, Gumbrell, M J, Millward, N P, Bailey, F, Doré-Green, F, Chapman, D, Simmons, M, Proctor |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Ovarian Neoplasms Dose-Response Relationship Drug Filgrastim Platelet Transfusion Adenocarcinoma Middle Aged Thrombocytopenia Drug Administration Schedule Recombinant Proteins Carboplatin Cohort Studies Leukocyte Count Treatment Outcome Granulocyte Colony-Stimulating Factor Humans Female Neoplasm Staging |
| Zdroj: | Seminars in oncology. 21(5 Suppl 12) |
| ISSN: | 0093-7754 |
| Popis: | A phase I study of frequently administered carboplatin with recombinant human granulocyte colony-stimulating factor (filgrastim) has been performed in patients with newly diagnosed epithelial ovarian cancer. Recombinant human granulocyte colony-stimulating factor was administered at a dose of 5 micrograms/kg/d for days 1 through 12 after carboplatin treatment. Carboplatin doses were calculated using a pharmacokinetic formula on an area under the curve (AUC) basis. Four doses of carboplatin were planned for each patient. The first cohort of patients received an AUC of 5 mg/mL x min every 3 weeks. Subsequently four additional cohorts received AUCs of 5, 7, 9, and 8 every 2 weeks. Non-hematologic toxicities were mild and not significant. The dose-limiting toxicity was thrombocytopenia and occurred at an AUC of 9. Most patients could complete treatment at an AUC of 7. Results for AUC 8 are awaited. Complete and partial responses were seen in most patients at all dose levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|